I went. It was a more professional affair this time but I was dissappointed by further hurdles and delays. I would not even consider entering again until substantial sales have been achieved.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025